“Ra-SBRT Is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients ”. Journal of Analytical Oncology, vol. 8, Nov. 2019, pp. 71-76, https://doi.org/10.30683/1927-7229.2019.08.10.